- Targeting chronic neuropathic pain biomarkers for drug development
B Moore, D Buckley, J Wren, D Finn, P McHugh
- Targeting cyclooxygenase-2 and oxidant stress pathways for attenuation of radiation-induced vascular dysfunction
Pietzsch J, Laube M, Ullm S, Sehn F, Pietzsch FJ, Kniess T
- Targeting muscarinic receptors rescues the cognitive deficit in prion neurodegenerative disease in mice
S Bradley, A Butcher, J Bourgognon, J Moreno, N Verity, L Broad, C Felder, A Tobin
- Targeting muscarinic receptor subtypes as a therapeutic approach in dystonia
D Klisko, P Jenner, S Rose
- Targeting neuroinflammatory pathways with novel and existing compounds for the development of analgesic therapeutics
B. J. Moore, B. Islam, P. C. McHugh. Centre for Biomarker Research, University of Huddersfield, Huddersfield, United Kingdom
- Targeting NF-kB inducing kinase (NIK) for developing anti-cancer drugs.
A Al-Obaidi, A McCluskey, A Sorensen, K H Ho, D Breen, G Berretta, A Alsfouk, C West, N Anthony, J Edwards, C Suckling, M Boyd, S MacKay, A Paul, R Plevin
- Targeting of Type I Protein Kinase A to lipid rafts is required for platelet inhibition by the cAMP-signaling pathway
Raslan Z, Aburima A, Magwenzi S, Tasken K, Naseem K
- Targeting p38? MAPK In Oesophageal Cancer: A Possible Future Therapeutic Goal?"
O Callaghan C, Fanning L, Houston A, Barry O
- Targeting SET-PP2A complex as a new avenue for therapeutic targeting of KMT2A-driven acute leukemia
Maria Teresa Esposito. University of Roehampton
- Targeting the hKv1.3 potassium channel in the development of novel treatments for autoimmune diseases
Tang Raymond, Milnes James, Louis Laurence, Wilson Jenny, Piotrowski Wojciech, Eastwood Sarah, Jones Simon, Mulla Mushtaq, Hamlyn Richard, Madge David, Ford John
